ClinicalTrials.gg
Active, not recruitingNCT05081609IL BelieveUpdated Oct 13, 2026

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

A Phase 1/2 interventional study of TransCon IL-2 β/γ and Pembrolizumab in Advanced Solid Tumor, Locally Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by Ascendis Pharma Oncology Division A/S. Active, not recruiting at 68 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Ascendis Pharma Oncology Division A/S · Phase 1/2, Interventional, and Treatment

How we know · 13 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
320
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 415 studies in Neoplasm Metastasis with a site in Spain — 79 open to participants now, 144 under way, 43 of them phase 3. Neoplasm Metastasis · Spain.

Enrollment
128th of 393
320 · median 163
Started
2022
with 34 others
Phase 1/2
65 of 415
23 open now
Primary completion
2027-08
later than 76 of 143 live
Registered
294th of 415
by date

Among the 415 studies in Neoplasm Metastasis with a site in Spain, this one is the 128th largest by enrollment of the 393 interventional ones that give a count, is one of 35 that started in 2022, is one of 65 in phase 1/2, reaches primary completion later than 76 of the 143 other live ones, and was the 294th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

79 of the 415 studies in Neoplasm Metastasis with a site in Spain are open now. Recruiting first, the newest first:

74 more — sign in →

All 79 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 415 studies in Neoplasm Metastasis with a site in Spain, or all of them as a file.
02

Study summary

TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This is a first-in-human, open-label, Phase 1/2, dose escalation and dose expansion study of TransCon IL-2 β/γ as monotherapy or in combination therapy in adult participants with advanced or metastatic solid tumors. Given the unique PK profile enabled by the TransCon technology, TransCon IL-2 β/γ presents the opportunity to enhance the therapeutic index of current IL-2 therapy.

Read the detailed description

IL-2 is a key cytokine that directs the immune system through pleiotropic effects mediated by promoting expansion of both cytotoxic effector cells and Tregs. TransCon IL-2 β/γ is designed as a long-acting delivery prodrug of IL-2 β/γ, a potent cytokine signaling molecule, with the potential to improve the safety and efficacy of IL-2.

03

Conditions studied

  • Advanced Solid Tumor
  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Platinum-resistant Ovarian Cancer
  • Post Anti-PD-1 Melanoma
  • 2L+ Cervical Cancer
  • Neoadjuvant Melanoma
  • Neoadjuvant Non-Small Cell Lung Cancer
  • Post Anti-PD-(L)1 Non-Small Cell Lung Cancer
  • Post Anti-PD-(L)1 Small Cell Lung Cancer
  • Third Line or Later (3L+) HER2+ Breast Cancer
  • Second or Third Line (2L/3L) Cervical Cancer
  • Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • At least 18 years of age, or country defined local legal age
  • Demonstrated adequate organ function at screening
  • >12 weeks as determined by the Investigator
  • Female and male participants of who are sexually active must agree to use highly effective methods of
  • Participants must have confirmed locally advanced, recurrent, or solid tumor that cannot be treated with curative intent (surgery or radiotherapy), with the exception of the cohorts
  • Part 1 and Part 2: (ECOG) performance status 0, 1, or 2
  • Part 3 and Part 4: Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Participants who have undergone treatment with , anti-PD-L1, or anti-cytotoxic T-lymphocyte-associated protein (CTLA-4) antibody must have a of at least 4 weeks from the last dose and evidence of disease progression per investigator assessment before Cycle 1 Day 1 (C1D1) with the exception of the neoadjuvant cohorts
  • Participants who have previously received an immunotherapy prior to C1D1 must have any immune-related toxicities resolved to ≤Grade 1 or baseline (prior to the immunotherapy) to be eligible, with the exception of participants on well controlled physiologic endocrine replacement
  • Part 3: Neoadjuvant cohorts: participants must have completely resectable disease

Key Exclusion Criteria:

  • Symptomatic central nervous system metastases and/or carcinomatous meningitis
  • Active diseases, regardless of need for treatment, with the exception of participants well controlled on physiologic endocrine replacement
  • Any uncontrolled bacterial, fungal, viral, or other infection
  • Significant cardiac disease
  • A marked baseline prolongation of /QTc interval (e.g., repeated demonstration of a QTc interval >480 ms) [ Grade 1]) using Fridericia's QT correction formula
  • Positive for (HIV) or has known active or C infection
  • Known to any study treatment(s) used in the specific study part/cohort
  • Participants who have been previously treated with IL-2 or IL-2 variants (all participants)
  • Systemic immunosuppressive treatment with the exception for patients on taper (for example, for exacerbation).
  • Vaccination with live, attenuated vaccines within 4 weeks of C1D1
  • Treatment with any other anti-cancer systemic treatment (approved or ) or radiation therapy within 4 weeks of C1D1
  • Part 3: Other active malignancies within the last 2 years
  • Women who are breastfeeding or have a positive serum pregnancy test during screening
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
320 participants (actual)

Study arms

  • Experimental
    Part 1 Monotherapy Dose Escalation: TransCon IL-2 β/γ

    TransCon IL-2 β/γ in escalating doses to evaluate safety/tolerability and to determine the MTD and RP2D

    Drug: TransCon IL-2 β/γ

  • Experimental
    Part 2 Combination Dose Escalation: TransCon IL-2 β/γ with Pembrolizumab

    TransCon IL-2 β/γ with Pembrolizumab in escalating doses to evaluate safety/tolerability and determine the MTD and RP2D

    Drug: TransCon IL-2 β/γ · Drug: Pembrolizumab

  • Experimental
    Part 3 Combination Dose Expansion: TransCon IL-2 β/γ with SOC Chemo

    TransCon IL-2 β/γ using the RP2D with SOC Chemotherapy to evaluate safety/tolerability and anti-tumor activity of the combination

    Drug: TransCon IL-2 β/γ · Drug: Chemotherapy drug

  • Experimental
    Part 3 Combination Dose Expansion: TransCon IL-2 β/γ with TransCon TLR7/8 Agonist

    TransCon IL-2 β/γ with TransCon TLR7/8 Agonist using the RP2D to evaluate safety/tolerability and anti-tumor activity of the combination

    Drug: TransCon IL-2 β/γ · Drug: TransCon TLR7/8 Agonist

  • Experimental
    Part 3 Monotherapy Dose Expansion: TransCon IL-2 β/γ followed by surgery

    (Optional Arm): TransCon IL-2 β/γ using the RP2D followed by surgery to evaluate safety/tolerability and anti-tumor activity of the combination

    Drug: TransCon IL-2 β/γ · Procedure: Surgery

  • Experimental
    Part 3 Combination Dose Expansion: TransCon IL-2 β/γ with Pembrolizumab followed by surgery

    TransCon IL-2 β/γ using the RP2D with Pembrolizumab followed by surgery to evaluate safety/tolerability and anti-tumor activity of the combination

    Drug: TransCon IL-2 β/γ · Drug: Pembrolizumab · Procedure: Surgery

  • Experimental
    Part 3 Combination Dose Expansion:TransCon IL-2 β/γ with TransCon TLR7/8 Agonist followed by surgery

    TransCon IL-2 β/γ with TransCon TLR7/8 Agonist using the RP2D followed by surgery to evaluate safety/tolerability and anti-tumor activity of the combination

    Drug: TransCon IL-2 β/γ · Drug: TransCon TLR7/8 Agonist · Procedure: Surgery

  • Experimental
    Part 3 Combination Dose Expansion:TransCon IL-2 β/γ + Pembrolizumab + SOC Chemo followed by surgery

    TransCon IL-2 β/γ using the RP2D with Pembrolizumab and SOC Chemotherapy followed by surgery to evaluate safety/tolerability and anti-tumor activity of the combination

    Drug: TransCon IL-2 β/γ · Drug: Pembrolizumab · Drug: Chemotherapy drug · Procedure: Surgery

  • Experimental
    Part 3 Combination Dose Expansion

    TransCon IL-2 β/γ + Pembrolizumab TransCon IL-2 β/γ using the RP2D with Pembrolizumab

    Drug: TransCon IL-2 β/γ · Drug: Pembrolizumab

  • Experimental
    Part 3 Combination Dose Expansion: TransCon IL-2 β/γ monotherapy

    TransCon IL-2 β/γ monotherapy

    Drug: TransCon IL-2 β/γ

  • Experimental
    Part 3 Combination Dose Expansion: TransCon IL-2 β/γ + trastuzumab

    TransCon IL-2 β/γ + trastuzumab

    Drug: TransCon IL-2 β/γ · Drug: Trastuzumab

  • Experimental
    Part 3 Combination Dose Expansion: TransCon IL-2 β/γ + trastuzumab emtansine (T-DM1)

    TransCon IL-2 β/γ + trastuzumab emtansine (T-DM1)

    Drug: TransCon IL-2 β/γ · Drug: Trastuzumab emtansine (T-DM1)

  • Experimental
    Part 4 Combination Dose Optimization

    TransCon IL-2 β/γ + Pembrolizumab TransCon IL-2 β/γ using the RP2D in titrating doses and/or different dose frequencies with Pembrolizumab

    Drug: TransCon IL-2 β/γ · Drug: Pembrolizumab

Interventions

  • DrugTransCon IL-2 β/γ

    TransCon IL-2 β/γ will be administered as an intravenous (IV) infusion

  • Pembrolizumab will be administered as an intravenous (IV) infusion

  • DrugChemotherapy drug

    SOC chemotherapy will be administered as an intravenous (IV) infusion

  • DrugTransCon TLR7/8 Agonist

    TransCon TLR7/8 Agonist will be administered as an IT (Intratumoral) injection

  • ProcedureSurgery

    Surgery will take place 4-6 weeks after last dose of study treatment.

  • Trastuzumab will be administered as an intravenous (IV) infusion

  • DrugAdo-Trastuzumab EmtansineStudies of Ado-Trastuzumab EmtansineAdo-Trastuzumab Emtansine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Trastuzumab emtansine (T-DM1) will be administered as an intravenous (IV) infusion

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    Treatment emergent and treatment related adverse events (assessed by NCI CTCAE v5.0), serious adverse events (SAEs), adverse events leading to treatment discontinuation, deaths.

    Time frame: Through study completion, expected average of 2 years

  2. Maximum Tolerated Dose (MTD)

    Determine the maximum tolerated dose by assessing the Incidence of Dose Limiting Toxicities (DLTs), treatment emergent and treatment related adverse events (assessed by NCI CTCAE v5.0), serious adverse events (SAEs), adverse events leading to treatment discontinuation and deaths.

    Time frame: Each cycle is 21 days

  3. Recommended Phase 2 Dose (RP2D)

    To determine a recommended phase 2 dose of TransCon IL-2 β/γ and combination regimen for further development by evaluating number of patients with treatment-related adverse events as assessed by CTCAE.

    Time frame: 12 months

Secondary outcomes

  1. Overall Response Rate

    Response assessed by RECIST v1.1

    Time frame: Average of 2 years

  2. Pathologic Complete Response

    Evaluate the pathologic Complete Response (pCR) for anti-tumor activity of TransCon IL-2 β/γ alone or in combination with pembrolizumab, or TransCon TLR7/8 Agonist, or in combination with pembrolizumab and SOC chemotherapy in the Neoadjuvant Cohorts

    Time frame: 15 weeks

  3. Major Pathologic Response

    Evaluate the Major Pathologic Response (MPR) for anti-tumor activity of TransCon IL-2 β/γ alone or in combination with pembrolizumab, or TransCon TLR7/8 Agonist, or in combination with pembrolizumab and SOC chemotherapy in the Neoadjuvant Cohorts

    Time frame: 15 weeks

  4. Duration of Response

    Time from first documentation of objective tumor response (CR or PR that is subsequently confirmed) to first documentation of disease progression or death due to any cause, whichever occurs first

    Time frame: Average of 2 years

  5. Time to Response

    Time from date of first dose of study treatment to first occurrence of response (CR or PR)

    Time frame: Expected up to 1 year from first dose

  6. Progression Free Survival (PFS)

    Time from date of first dose of study treatment to first documentation of disease progression or death due to any cause

    Time frame: Average of 2 years

  7. Event free survival (EFS) by RECIST 1.1

    Time from the date of the first dose of study treatment to the occurrence of any of the following: progression of disease that precludes surgery, disease recurrence after surgery, or death from any cause.

    Time frame: 2 years

  8. Overall Survival (OS)

    Time from date of first dose of study treatment to date of death due to any cause

    Time frame: Average of 2 years

  9. PK Characterization (Cmax)

    Maximum observed plasma concentration of TransCon IL-2 β/γ and Free IL-2 β/γ after IV administration of TransCon IL-2 β/γ alone or in combination with other therapies

    Time frame: Average of 2 years

  10. PK Characterization (Tmax)

    Time to reach maximum plasma concentration of TransCon IL-2 β/γ and Free IL-2 β/γ after IV administration of TransCon IL-2 β/γ alone or in combination other therapies

    Time frame: Average of 2 years

  11. PK Characterization (AUClast)

    Area under the plasma concentration curve from time zero to last sampling time at which the concentration is at or above the lower limit of quantification for TransCon IL-2 β/γ and Free IL-2 β/γ after IV administration of TransCon IL-2 β/γ alone or in combination with other therapies

    Time frame: Average of 2 years

  12. PK Characterization (AUC0-t)

    Area under the plasma concentration curve from time zero to time t for TransCon IL-2 β/γ and Free IL-2 β/γ after IV administration of TransCon IL-2 β/γ alone or in combination with other therapies

    Time frame: Average of 2 years

  13. PK Characterization (t1/2)

    Apparent terminal half-life of TransCon IL-2 β/γ and Free IL-2 β/γ after IV administration of TransCon IL-2 β/γ alone or in combination with other therapies

    Time frame: Average of 2 years

07

Study locations

68 sites
  • Ascendis Pharma Investigational Site
    Los Angeles, California 90048, United States
  • Ascendis Pharma Investigational Site
    Los Angeles, California 90067, United States
  • Ascendis Pharma Investigational Site
    Springfield, Illinois 62702, United States
  • Ascendis Pharma Investigational Site
    Louisville, Kentucky 40202, United States
  • Ascendis Pharma Investigational Site
    Boston, Massachusetts 02114, United States
  • Ascendis Pharma Investigational Site
    Morristown, New Jersey 07960, United States
  • Ascendis Pharma Investigational Site
    New York, New York 10032, United States
  • Ascendis Pharma Investigational Site
    Huntersville, North Carolina 28078, United States
  • Ascendis Pharma Investigational Site
    Canton, Ohio 44718, United States
  • Ascendis Pharma Investigational Site
    Cincinnati, Ohio 45219, United States
  • Ascendis Pharma Investigational Site
    Oklahoma City, Oklahoma 73104, United States
  • Ascendis Pharma Investigational Site
    Pittsburgh, Pennsylvania 15232, United States
  • Ascendis Pharma Investigational Site
    Nashville, Tennessee 37203, United States
  • Ascendis Pharma Investigational Site
    Richmond, Virginia 23298, United States
  • Ascendis Pharma Investigational Site
    Adelaide, 5000, Australia
  • Ascendis Pharma Investigational Site
    Adelaide, 5042, Australia
  • Ascendis Pharma Investigational Site
    Brisbane, 04120, Australia
  • Ascendis Pharma Investigational Site
    Frankston, 3199, Australia
  • Ascendis Pharma Investigational Site
    Southport, 4215, Australia
  • Ascendis Pharma Investigational Site
    Toorak Gardens, 05065, Australia
  • Ascendis Pharma Investigational Site
    Waratah, 2298, Australia
  • Ascendis Pharma Investigational Site
    Wilrijk, 2610, Belgium
  • Ascendis Pharma Investigational Site
    Montreal, H4A 3J1, Canada
  • Ascendis Pharma Investigational Site
    Toronto, M4N 3M5, Canada
  • Ascendis Pharma Investigational Site
    Toronto, M5G 2C4, Canada
  • Ascendis Pharma Investigational Site
    Cuneo, 12100, Italy
  • Ascendis Pharma Investigational Site
    Florence, 50134, Italy
  • Ascendis Pharma Investigational Site
    Grosseto, 58100, Italy
  • Ascendis Pharma Investigational Site
    Lido di Camaiore, 55041, Italy
  • Ascendis Pharma Investigational Site
    Livorno, 57124, Italy
  • Ascendis Pharma Investigational Site
    Meldola, 47014, Italy
  • Ascendis Pharma Investigational Site
    Milan, 20133, Italy
  • Ascendis Pharma Investigational Site
    Milan, 20141, Italy
  • Ascendis Pharma Investigational Site
    Modena, 41124, Italy
  • Ascendis Pharma Investigational Site
    Roma, 00167, Italy
  • Ascendis Pharma Investigational Site
    Torino, 10126, Italy
  • Ascendis Pharma Investigational Site
    Turin, 10060, Italy
  • Ascendis Pharma Investigational Site
    Verona, 37134, Italy
  • Ascendis Pharma Investigational Site
    Krakow, 31-501, Poland
  • Ascendis Pharma Investigational Site
    Poznan, 60693, Poland
  • Ascendis Pharma Investigational Site
    Warsaw, 02-781, Poland
  • Ascendis Pharma Investigational Site
    Singapore, 119228, Singapore
  • Ascendis Pharma Investigational Site
    Singapore, 217562, Singapore
  • Ascendis Pharma Investigational Site
    Seoul, Songpa-gu 05505, South Korea
  • Ascendis Pharma Investigational Site
    Seongnam-si, 13620, South Korea
  • Ascendis Pharma Investigational Site
    Seoul, 03080, South Korea
  • Ascendis Pharma Investigational Site
    Seoul, 03722, South Korea
  • Ascendis Pharma Investigational Site
    Seoul, 06231, South Korea
  • Ascendis Pharma Investigational Site
    Seoul, 06351, South Korea
  • Ascendis Pharma Investigational Site
    Barcelona, 08023, Spain
  • Ascendis Pharma Investigational Site
    Barcelona, 08028, Spain
  • Ascendis Pharma Investigational Site
    Barcelona, 08035, Spain
  • Ascendis Pharma Investigational Site
    L'Hospitalet de Llobregat, 08908, Spain
  • Ascendis Pharma Investigational Site
    Madrid, 28006, Spain
  • Ascendis Pharma Investigational Site
    Madrid, 28027, Spain
  • Ascendis Pharma Investigational Site
    Madrid, 28040, Spain
  • Ascendis Pharma Investigational Site
    Madrid, 28041, Spain
  • Ascendis Pharma Investigational Site
    Madrid, 28050, Spain
  • Ascendis Pharma Investigational Site
    Málaga, 29010, Spain
  • Ascendis Pharma Investigational Site
    Murcia, 30120, Spain
  • Ascendis Pharma Investigational Site
    Oviedo, 33011, Spain
  • Ascendis Pharma Investigational Site
    Pamplona, 31008, Spain
  • Ascendis Pharma Investigational Site
    Seville, 41009, Spain
  • Ascendis Pharma Investigational Site
    Seville, 41014, Spain
  • Ascendis Pharma Investigational Site
    Valencia, 46009, Spain
  • Ascendis Pharma Investigational Site
    Valencia, 46014, Spain
  • Ascendis Pharma Investigational Site
    Taipei, 10002, Taiwan
  • Ascendis Pharma Investigational Site
    Taipei, 11259, Taiwan
08

References and documents

Publications

  • Rosen DB, Kvarnhammar AM, Laufer B, Knappe T, Karlsson JJ, Hong E, Lee YC, Thakar D, Zuniga LA, Bang K, Sabharwal SS, Uppal K, Olling JD, Kjaergaard K, Kurpiers T, Schnabel M, Reich D, Glock P, Zettler J, Krusch M, Bernhard A, Heinig S, Konjik V, Wegge T, Hehn Y, Killian S, Viet L, Runz J, Faltinger F, Tabrizi M, Abel KL, Breinholt VM, Singel SM, Sprogoe K, Punnonen J. TransCon IL-2 beta/gamma: a novel long-acting prodrug with sustained release of an IL-2Rbeta/gamma-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer. J Immunother Cancer. 2022 Jul;10(7):e004991. doi: 10.1136/jitc-2022-004991. PubMed 35817480 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Aug 2027, 67 months after the start.

Of 129 industry-sponsored phase 1/2 interventional studies under Neoplasm Metastasis, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 89. This study's planned 67 months is above that.

Counting every sponsor, half of 215 studies reached it within 62 months; a quarter within 42 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2021
First posted
Oct 18, 2021
StartActual
Jan 11, 2022
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2029
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05081609
Lead sponsor
Ascendis Pharma Oncology Division A/S
Responsible party
Sponsor
First posted
Oct 18, 2021
Start date
Jan 11, 2022
Primary completion
Aug 2027 (estimated)
Completion
Aug 2029 (estimated)
Last update
Oct 13, 2026

Study contacts

Davis Torrejon-Castro
study director · Medical Monitor

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion